{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:17:55Z","timestamp":1762157875177,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oral Radiol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11282-022-00594-2","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T16:02:30Z","timestamp":1644508950000},"page":"594-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of zoledronic acid and denosumab on the mandible and other bones: a 18F-NaF-PET study"],"prefix":"10.1007","volume":"38","author":[{"given":"Mao","family":"Fushimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Ohbayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumi","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Norikane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-9704","authenticated-orcid":false,"given":"Minoru","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"594_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165\u201376.","journal-title":"Cancer Treat Rev"},{"key":"594_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11864-005-0023-0","volume":"6","author":"A Lipton","year":"2005","unstructured":"Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005;6:161\u201371.","journal-title":"Curr Treat Options Oncol"},{"key":"594_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61\u20136.","journal-title":"Br J Cancer"},{"key":"594_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/0277-5379(90)90080-D","volume":"26","author":"SM O'Reilly","year":"1990","unstructured":"O\u2019Reilly SM, Richards MA, Rubens RD. Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer (Oxford, England: 1990). 1990;26:574\u20137.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"594_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/02841860701233435","volume":"46","author":"S Wu","year":"2007","unstructured":"Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in cancer patients. Acta Oncol. 2007;46:581\u201391.","journal-title":"Acta Oncol"},{"key":"594_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126:13\u201320.","journal-title":"Am J Med"},{"key":"594_CR7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg. 2014;72:1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"key":"594_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3\u201323.","journal-title":"J Bone Miner Res"},{"key":"594_CR9","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s12885-019-6236-6","volume":"19","author":"M Takahashi","year":"2019","unstructured":"Takahashi M, Ozaki Y, Kizawa R, et al. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer. 2019;19:980.","journal-title":"BMC Cancer"},{"key":"594_CR10","first-page":"e326","volume":"25","author":"A Limones","year":"2020","unstructured":"Limones A, S\u00e1ez-Alcaide LM, D\u00edaz-Parre\u00f1o SA, et al. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: a systematic review and meta-analysis. Med Oral Patologia Oral y Cirugia Bucal. 2020;25:e326\u201336.","journal-title":"Med Oral Patologia Oral y Cirugia Bucal"},{"key":"594_CR11","doi-asserted-by":"publisher","first-page":"100259","DOI":"10.1016\/j.jbo.2019.100259","volume":"18","author":"M Lockwood","year":"2019","unstructured":"Lockwood M, Banderudrappagari R, Suva LJ, Makhoul I. Atypical femoral fractures from bisphosphonate in cancer patients\u2014review. J Bone Oncol. 2019;18:100259.","journal-title":"J Bone Oncol"},{"key":"594_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1\u201323.","journal-title":"J Bone Miner Res"},{"key":"594_CR13","doi-asserted-by":"publisher","first-page":"36129","DOI":"10.1038\/srep36129","volume":"7","author":"X Gong","year":"2017","unstructured":"Gong X, Yu W, Zhao H, Su J, Sheng Q. Skeletal site-specific effects of zoledronate on in vivo bone remodeling and in vitro BMSCs Osteogenic Activity. Sci Rep. 2017;7:36129.","journal-title":"Sci Rep"},{"key":"594_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s11914-018-0474-4","volume":"16","author":"J Chang","year":"2018","unstructured":"Chang J, Hakam AE, McCauley LK. Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr Osteoporos Rep. 2018;16:584\u201395.","journal-title":"Curr Osteoporos Rep"},{"key":"594_CR15","first-page":"332","volume":"3","author":"M Blau","year":"1962","unstructured":"Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332\u20134.","journal-title":"J Nucl Med"},{"key":"594_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bone.2011.09.053","volume":"50","author":"Y Li","year":"2012","unstructured":"Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR. Clinical utility of 18F-fluoride PET\/CT in benign and malignant bone diseases. Bone. 2012;50:128\u201339.","journal-title":"Bone"},{"key":"594_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1053\/j.semnuclmed.2007.07.002","volume":"37","author":"E Even-Sapir","year":"2007","unstructured":"Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-fluoride positron emission tomography and positron emission tomography\/computed tomography. Semin Nucl Med. 2007;37:462\u20139.","journal-title":"Semin Nucl Med"},{"key":"594_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2967\/jnumed.106.037200","volume":"49","author":"FD Grant","year":"2008","unstructured":"Grant FD, Fahey FH, Packard AB, et al. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68\u201378.","journal-title":"J Nucl Med"},{"key":"594_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1053\/j.semnuclmed.2016.07.003","volume":"46","author":"W Langsteger","year":"2016","unstructured":"Langsteger W, Rezaee A, Pirich C, Beheshti M. (18)F-NaF-PET\/CT and (99m)Tc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med. 2016;46:491\u2013501.","journal-title":"Semin Nucl Med"},{"key":"594_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.bjoms.2014.01.021","volume":"52","author":"O Ristow","year":"2014","unstructured":"Ristow O, Gerngro\u00df C, Schwaiger M, et al. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates. Br J Oral Maxillofac Surg. 2014;52:308\u201313.","journal-title":"Br J Oral Maxillofac Surg"},{"key":"594_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677\u201392.","journal-title":"Bone"},{"key":"594_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bone.2010.08.011","volume":"49","author":"LI Plotkin","year":"2011","unstructured":"Plotkin LI, Bivi N, Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone. 2011;49:122\u20137.","journal-title":"Bone"},{"key":"594_CR23","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150\u20137.","journal-title":"J Clin Oncol"},{"key":"594_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.addr.2015.10.005","volume":"99","author":"L Cole","year":"2015","unstructured":"Cole L, Vargo-Gogola T, Roeder R. Targeted delivery to bone and mineral deposits using bisphosphonate ligands. Adv Drug Deliv Rev. 2015;99:12.","journal-title":"Adv Drug Deliv Rev"},{"key":"594_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18:75\u201385.","journal-title":"Bone"},{"key":"594_CR26","first-page":"115","volume":"21","author":"SC Manolagas","year":"2000","unstructured":"Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis*. Endocr Rev. 2000;21:115\u201337.","journal-title":"Endocr Rev"},{"key":"594_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2485\/jhtb.23.267","volume":"23","author":"T Matsuura","year":"2014","unstructured":"Matsuura T, Mizumachi E, Katafuchi M, et al. Sex-related differences in cortical and trabecular bone quantities at the mandibular molar. J Hard Tissue Biol. 2014;23:267\u201374.","journal-title":"J Hard Tissue Biol"},{"key":"594_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0001-2998(72)80005-9","volume":"2","author":"M Blau","year":"1972","unstructured":"Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging. Semin Nucl Med. 1972;2:31\u20137.","journal-title":"Semin Nucl Med"},{"key":"594_CR29","first-page":"47","volume":"45","author":"GJ Cook","year":"2001","unstructured":"Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med. 2001;45:47\u201352.","journal-title":"Q J Nucl Med"},{"key":"594_CR30","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1007\/s00259-012-2195-8","volume":"39","author":"DC Bortot","year":"2012","unstructured":"Bortot DC, Amorim BJ, Oki GC, et al. 18F-Fluoride PET\/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:1730\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"594_CR31","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/MNM.0000000000000720","volume":"38","author":"I Sarikaya","year":"2017","unstructured":"Sarikaya I, Elgazzar AH, Sarikaya A, Alfeeli M. Normal bone and soft tissue distribution of fluorine-18-sodium fluoride and artifacts on 18F-NaF PET\/CT bone scan: a pictorial review. Nucl Med Commun. 2017;38:810\u20139.","journal-title":"Nucl Med Commun"},{"key":"594_CR32","doi-asserted-by":"publisher","first-page":"e108429-e","DOI":"10.1371\/journal.pone.0108429","volume":"9","author":"AZ Win","year":"2014","unstructured":"Win AZ, Aparici CM. Normal SUV values measured from NaF18- PET\/CT bone scan studies. PLoS ONE. 2014;9:e108429-e.","journal-title":"PLoS ONE"},{"key":"594_CR33","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","volume":"14","author":"N Raje","year":"2008","unstructured":"Raje N, Woo S-B, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14:2387\u201395.","journal-title":"Clin Cancer Res"},{"key":"594_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.joms.2008.12.002","volume":"67","author":"K Arce","year":"2009","unstructured":"Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009;67:75\u201384.","journal-title":"J Oral Maxillofac Surg"},{"key":"594_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.tripleo.2008.09.019","volume":"107","author":"F Wilde","year":"2009","unstructured":"Wilde F, Steinhoff K, Frerich B, et al. Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2009;107:412\u20139.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol"}],"container-title":["Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11282-022-00594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11282-022-00594-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11282-022-00594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T03:36:10Z","timestamp":1663212970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11282-022-00594-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1007\/s11282-022-00594-2","relation":{},"ISSN":["0911-6028","1613-9674"],"issn-type":[{"type":"print","value":"0911-6028"},{"type":"electronic","value":"1613-9674"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (the Kagawa University Ethical Committee (2020-#122)) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}